363 patents currently held
667 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Of the 667 now held by other companies, 285 name Vantive Health GmbH as their current owner, and 382 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
61
Ending by 2030
Jan 2027
Next term end
241
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2036 · High confidence
Also notable
Ends May 2040 · High confidence
Also notable
Ends Dec 2031 · High confidence
Also notable
Ends no later than Nov 2031 · Medium confidence
Also notable
Ends Oct 2033 · High confidence
Also notable
Ends May 2038 · High confidence
Also notable
Ends Apr 2028 · High confidence
Also notable
Ends Jul 2031 · High confidence
Medical Device Data Integration Apparatus and Methods
US 10,071,202
Cited by 70 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Medical Device Data Back-Association System, Apparatuses, and Methods
US 11,177,026
Cited by 55 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2040.
Infusion System Using Optical Imager for Controlling Flow and Method Thereof
US 8,622,979
Cited by 60 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Dynamically Variable Filter
US 9,095,271
Cited by 45 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Drip Chamber with Integrated Optics
US 9,234,850
Cited by 52 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Infusion Pump Door Seal for Vertical Intravenous Tubes
US 10,648,564
Cited by 17 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2038.
Pain Controlled Analgesic ("PCA") Apparatus
US 7,914,483
Cited by 52 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Hemostatic Sponge
US 8,703,170
Cited by 31 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Jan 2027 · Medium confidence
The most cited patent in this portfolio, cited by 325 later US patents, top 1% of utility patents granted in 2011 in our data. Protection runs to 2027.
now held by Vantive Health GmbH
Also notable
Ends Jul 2034 · High confidence
Cited by 229 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
now held by Vantive Health GmbH
Also notable
Ends Dec 2036 · Medium confidence
Cited by 76 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2036.
now held by Vantive Health GmbH
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 2, 2026The maintenance fee for Method for delivering drugs to the brain (US 9,044,381) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 8 fees due Jan 2 to 25, 2027 · next Jan 2
- 9 fees due Feb 1 to 28, 2027 · next Feb 1
- 7 fees due Mar 8 to 29, 2027 · next Mar 8
- 11 fees due Apr 1 to 29, 2027 · next Apr 1
- 2 fees due May 10 to 21, 2027 · next May 10
- 9 fees due Jun 5 to 29, 2027 · next Jun 5
- 2 fees due Jul 12 to 30, 2027 · next Jul 12
- 3 fees due Aug 2 to 16, 2027 · next Aug 2
- 3 fees due Sep 8 to 19, 2027 · next Sep 8
- 9 fees due Oct 9 to 28, 2027 · next Oct 9
- 6 fees due Nov 7 to 17, 2027 · next Nov 7
Recent changes
- 35 of the patents on this record were granted since Aug 23, 2026
- 17 terms have ended since Aug 23, 2026
- Nov 20 US 8,333,959 Ex-Vivo Application of Solid Microparticulate Therapeutic Agents · term ended
- Nov 14 US 7,642,271 Argatroban Formulation · term ended
- Nov 6 US 7,776,360 (POLYALKOXY)SULFONATE Surface Modifiers · term ended
- Oct 28 US 8,871,949 Method for Preparing Fmoc-Based Hydrolysable Linkers · lapsed on the fee record
- Oct 25 US 7,733,892 Buffer Management Method Based on a Bitmap Table · term ended
- Oct 21 US 8,868,350 Therapy Prediction and Optimization for Renal Failure Blood Therapy, Especially Home Hemodialysis · lapsed on the fee record
- Oct 21 US 8,865,450 Method for Producing Continuous Cell Lines · lapsed on the fee record
- Oct 19 US 7,699,806 Medical Fluid Therapy Flow Balancing and Synchronization Method and Apparatus · term ended
- Oct 14 US 8,858,792 Hemodialysis and Peritoneal Dialysis Systems Having Electrodeionization Capabilities · lapsed on the fee record
- Oct 14 US 8,858,787 Dialysis System Having Non-Invasive Fluid Velocity Sensing · lapsed on the fee record
- Sep 30 US 8,846,620 Resorption Enhancers as Additives to Improve the Oral Formulation of Non-Anticoagulant Sulfated Polysaccharides · lapsed on the fee record
- Sep 23 US 8,841,248 Manufacture of Inter-Alpha-Inhibitor (IaIp) from Plasma · lapsed on the fee record
- Sep 10 US 11,124,787 ADAMTS13-Containing Compositions Having Thrombolytic Activity · term ended
- Sep 2 US 8,822,638 Biologically Active Peptides · lapsed on the fee record
- Aug 28 US 8,034,830 Argatroban Formulation · term ended
What they patent
The largest of its 241 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,762,795 | Rotary Axial Peristaltic Pumps and Related Methods held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 7,537,174 | Hand Triggered Tissue Sealant Spray Apparatus and System held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 11,896,939 | Device, System and Method for Mixing held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 9,821,001 | Novel Aminoglycosides and Uses Thereof in the Treatment of Genetic Disorders held by Baxter International Inc. and Baxter Healthcare S.A. In force · Low confidence | In force | Low confidence | |
| US 8,703,122 | Method for Directed Cell In-Growth and Controlled Tissue Regeneration in Spinal Surgery held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 8,834,864 | Methods for repairing and regenerating human dura mater held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 8,722,736 | Multi-Dose Concentrate Esmolol with Benzyl Alcohol held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 7,605,291 | Method for the Preparation of Volatile Anesthetics held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 10,166,514 | Device, System and Method for Mixing held by Baxter International Inc. and Baxter Healthcare S.A. In force · High confidence | In force | High confidence | |
| US 9,724,449 | Injectable Fibrin Composition for Bone Augmentation held by Baxter International Inc. and Baxter Healthcare, S.A. In force · High confidence | In force | High confidence |
Also on record, not counted in the 363: 667 patents in force now held by others · 529 patents ended · 210 applications pending · 397 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.